Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo

Journal of Neurochemistry

Volumn 66, Issue 5, 1996, Pages 1949-1958

  Finnegan, Kevin T ^a,b,c   Taraska, Terri ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c V A Medical Center   (United States)

Author keywords

3,4 Methylenedioxymethamphetamine; Dopamine; Glutamate; Glutamate antagonists; Methamphetamine; Striatum

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; METHAMPHETAMINE;

ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; MALE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; AMINES; ANIMALS; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATES; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPECOLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029981832     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66051949.x     Document Type: Article

References (69)

1. Abekawa T., Ohmori T., and Koyama T. (1994) Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res. 643, 276-281.
2. Altar C. A., Dugich D. M., Armanini M., and Bakhit C. (1991) Medial-to-lateral gradient of neostriatal NGF receptors: relationship to cholinergic neurons and NGF-like immunoreactivity. J. Neurosci. 11, 828-836.
3. Barbeito L., Cheramy A., Godeheu G., Desce J. M., and Glowinski J. (1990) Glutamate receptors of a quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur. J. Neurosci. 28, 365-374.
4. Benveniste H., Drejer J., Schousboe A., and Diemer N. H. (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43, 1369-1374.
5. Bouyer J. J., Park D. H., Joh T. H., and Pickel V. M. (1984) Chemical and structural analysis of the relation between cortical inputs and tyrosine-hydroxylase containing terminals in rat neostriatum. Brain Res. 302, 267-275.
6. 3H] dopamine from striatal slices. J. Pharmacol. Exp. Ther. 257, 262-270.
7. Bowyer J. F., Gough B., Slikker W. Jr., Lipe G. W., Newport G. D., and Holson R. R. (1993) Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol Biochem. Behav. 44, 87-98.
8. Bowyer J. P., Davies D. L., Schmued L., Broening H. W., Newport G. D., Slikker W. Jr., and Holson R R. (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268, 1571-1580.
9. Carlsson M. and Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
10. Carter C. J., L'Heureux R., and Scatton B. (1988) Differential control by N-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study. J. Neurochem. 51, 462-468.
11. Cheramy A , Romo R., Godeheu G , Baruch P., and Glowinski J. (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus - II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 19, 1081-1090.
12. Clow D. W. and Jhamandas K. (1989) Characterization of l-glutamate action on the release of endogenous dopamine from the rat caudate-putamen. J. Pharmacol. Exp. Ther. 248, 722-728.
13. Dahlstrom A. and Fuxe K. (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 62, 1-55.
14. Farfel G. M. and Seiden L. S. (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J. Pharmacol. Exp. Ther. 272, 860-867.
15. Farfel G. M., Vosmer G. L., and Seiden L. S. (1992) The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res. 595, 121-127.
16. Finnegan K. T., DeLanney L. E., Irwin I., Ricaurte G. A., and Langston J. W. (1989) The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age. Brain Res. 496, 251-256.
17. Finnegan K. T., Skratt J. J., Irwin I., and Langston J. W. (1990) The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of MDMA in rats. Neurosci. Lett. 105, 300-306.
18. Freund T. F., Powell J. F., and Smith A. D. (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13, 1189-1215.
19. Frotscher M., Rinne U., Hassler R., and Wagner A. (1981) Termination of cortical afferents on identified neurons in the caudate nucleus of the cat. Exp. Brain Res. 41, 329-337.
20. Fuller R. W. and Hemrick-Leucke S. (1980) Long-lasting depletion of neostriatal dopamine by a single injection of amphetamine in ipridole-treated rats. Science 209, 305-307.
21. 3H-catecholamines by rat striatal and hypothalamic synaptosomes. Life Sci. 18, 1105-1110.
22. Gibb J. W., Johnson M., and Hanson G. R. (1990) Neurochemical basis of neurotoxicity. Neurotoxicology 11, 317-321.
23. Giorguieff M. F., Kemel M. L., and Glowinski J. (1977) Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci. Lett. 6, 73-77.
24. Girault J. A., Spampinato U., Desban M., Glowinski J., and Beeson M. J. (1986) Enhancement of glutamate release in the rat striatum following electrical stimulation of the nigrothalamic pathway. Brain Res. 374, 363-366.
25. Girault J. A., Walaas S. I., Hemmings H. J., and Greengard P. (1990) ARPP-21, a cAMP-regulated phosphoprotein enriched in dopamine-innervated brain regions: tissue distribution and regulation of phosphorylation in rat brain. Neuroscience 37, 317-325.
26. Globus M. Y. T., Ginsberg M. D., Dietrich W. D., Busto R., and Scheinberg P. (1987) Substantia nigra lesion protects against ischemic damage in the striatum. Neurosci. Lett. 80, 251-256.
27. Graybiel A. M. (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-254.
28. Hanson G. R., Sonsalla P., Letter A., Merchant K. M., Johnson M., Bush L., and Gibb J. W. (1989) Effects of amphetamine analogs on central nervous system neuropeptide systems. NIDA Res. Monogr. 94, 259-269.
29. Imperato A., Honore T., and Jensen L. H. (1990) Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res. 530, 223-228.
30. Jhamandas K. and Marien M. (1987) Glutamate evoked release of endogenous brain dopamine: inhibition by an excitatory amino acid antagonist and an enkephalin analog. Br. J. Pharmacol. 90, 641-650.
31. Johnson K. and Robertson H. A. (1989) The NMDA antagonist MK-801 reverses d-amphetamine induced activation of the protooncogene c-fos in rat striatum. Soc. Neurosci. Abstr. 15, 782.
32. Johnson M., Bush L. G., Gibb J. W., and Hanson G. R. (1991) Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems. Eur. J. Pharmacol. 193, 367-370.
33. Karler R., Calder L. D., Thai L. H., and Bedingfield J. B. (1994) A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine. Brain Res. 658, 8-14.
34. Keefe K. A., Zigmond M. J., and Abercrombie E. D. (1992) Extracellular dopamine in striatum: influence of nerve impulse activity in medial forebrain bundle and local glutamatergic input. Neuroscience 47, 325-332.
35. Keefe K. A., Zigmond M. J., and Abercrombie E. D. (1993a) In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids. J. Neural Transm. 91, 223-240.
36. Keefe K. A., Sved A. F., Zigmond M. J., and Abercrombie E. D. (1993b) Stress-induced dopamine release in the neostriatum: evaluation of the role of action potentials in nigrostriatal dopamine neurons or local initiation by endogenous excitatory amino acids. J. Neurochem. 61, 1943-1952.
37. Kelly A. E. and Throne L. C. (1992) NMDA receptors mediate the behavioral effects of amphetamine infused into the nucleus accumbens. Brain Res. Bull. 29, 247-254.
38. Kim J. S., Hassler R., Haug P., and Paik K. S. (1977) Effect of frontal cortex ablation on striatal glutamic acid level in rat. Brain Res. 132, 370-374.
39. Leviel V., Gobert A., and Guibert B. (1990) The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience 39, 305-312.
40. ++-independent dopamine release from striatal slices: a possible role of reverse dopamine transport. J. Pharmacol. Exp. Ther. 256, 1132-1138.
41. 3H-dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid. Can. J. Physiol. Pharmacol. 61, 43-60.
42. Masuo Y., Montagne M. N., Pelaprat C., Scherman D., and Rostene W. (1990) Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density. Brain Res. 520, 6-13.
43. McGeer P. L., McGeer E. G., Scherer U., and Singh K. (1977) A glutamatergic corticostriatal path? Brain Res. 128, 369-373.
44. Moghaddam B. and Gruen R. J. (1991) Do endogenous excitatory amino acids influence striatal dopamine release? Brain Res. 544, 329-330.
45. Moghaddam B., Gruen R. J., Roth R. H., Bunney B. S., and Adams R. N. (1990) Effect of L-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res. 518, 55-60.
46. Moore R. Y., Bhatnagar R. K., and Heller A. (1971) Anatomical and chemical studies of a nigro-neostriatal projection in the cat. Brain Res. 30, 119-135.
47. Mora F. and Porras A. (1992) Effects of amphetamine on the release of excitatory amino acid neurotransmitters in the basal ganglia of the conscious rat. Can. J. Physiol. Pharmacol. 71, 348-351.
48. Nash J. F. and Brodkin J. (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259, 820-825.
49. Nash J. F. and Yamamoto B. K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237-243.
50. Nash J. F. and Yamamoto B. K. (1993) Effect of D-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats. Brain Res. 627, 1-8.
51. O'Dell S. J., Weihmuller F. B., and Marshall J. F. (1991) Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564, 256-260.
52. 2 antagonists. J. Neurochem. 60, 1792-1799.
53. O'Dell S. J., Weihmuller F. B., McPherson R. J., and Marshall J. F. (1994) Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions. J. Pharmacol. Exp. Ther. 269, 1319-1325.
54. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney.
55. Raiteri M., Cerito F., Cervoni A., and Levi G. (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208, 195-202.
56. Rao T. S., Cler J. A., Mick S. J., Emmett M. R., Farah J. M. Jr., Contreras P. C., Iyengar S., and Wood P. L. (1991) Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway. J. Neurochem. 56, 907-913.
57. 3H]-dopamine from rat striatum: an in vitro model for glutamate actions. J. Neurochem. 32, 1539-1545.
58. Seiden L. S. and Ricaurte G. A. (1987) Neurotoxicity of methamphetamine and related drugs, in Psychopharmacology: A Third Generation of Progress (Meltzer H. Y., ed), pp. 359-366. Raven Press, New York.
59. Shimizu N., Duan S., Hori T., and Oomura Y. (1990) Glutamate modulates dopamine release in the striatum as measured by brain microdialysis. Brain Res. Bull. 25, 99-102.
60. Singh N. A., Midgley L. P., Bush L. G., Gibb J. W., and Hanson G. R. (1991) N-Methyl-D-aspartate receptors mediate dopamine-induccd changes in extrapyramidal and limbic dynorphin systems. Brain Res. 555, 233-238.
61. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
62. Stephans S. E. and Yamamoto B. K. (1994) Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17, 203-209.
63. Stone D. M., Johnson M., Hanson G. R., and Gibb J. W. (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79-87.
64. Weihmuller F. B., O'Dell S. J., and Marshall J. F. (1992) MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow. Synapse 11, 155-163.
65. Weiloch T. (1985) Hypoglycemic-induced neuronal damage is prevented by an N-methyl-D-aspartate antagonist. Science 230, 681-683.
66. Weinberger J., Nieves-Rosa J., and Cohen G. (1985) Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine. Stroke 16, 864-870.
67. 3H-dopamine release from guinea pig striatum by NMDA receptor/channel activators and inhibitors. J. Pharmacol. Exp. Ther. 255, 40-45.
68. Yamamoto B. K. and Spanos L. J. (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148, 195-203.
69. Youngren K. D., Daly D. A., and Moghaddam B. (1993) Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 264, 289-293.